Cancer

publication venue for

Osteochondroma in long-term survivors of high-risk neuroblastoma. 2015
Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab. 2011
Cytologic diagnosis of Burkitt lymphoma. 2005
Cytologic features of the nested variant of urothelial carcinoma: a study of seven cases. 2003
Intra-abdominal fibrosis after systemic and intraperitoneal therapy containing fluoropyrimidines. 2000
Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. 1999
5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. 1999
Listeriosis in pediatric oncology patients. 1998
Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin--a case report. 1997
Acute pancreatitis associated with continuous infusion cytarabine therapy: a case report. 1996
Malignant mesenchymoma. 1996
Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. 1995
Clonal changes in inflammatory pseudotumor of the lung: a case report. 1995
Molecular genetic analysis demonstrates that multiple posttransplantation lymphoproliferative disorders occurring in one anatomic site in a single patient represent distinct primary lymphoid neoplasms. 1995
Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase. 1994
Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. 1994
Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. 1993
Treatment-related esophageal stricture in pediatric patients with cancer. 1993
Epithelioid osteosarcoma of bone. Immunocytochemical evidence suggesting divergent epithelial and mesenchymal differentiation in a primary osseous neoplasm. 1993
Immune-mediated thrombocytopenia secondary to suramin. 1993
Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity. 1992
Necrotizing pneumonitis caused by 5-fluorouracil infusion. A complication of a Hickman catheter. 1992
T-cell chronic lymphocytic leukemia. Unusual morphologic, phenotypic, and karyotypic features in association with light chain amyloidosis. 1992
Extraneural metastases of infratentorial glioblastoma multiforme to the peritoneal cavity. 1992
Production of granulocyte-macrophage colony-stimulating factor in two patients with lung cancer, leukocytosis, and eosinophilia. 1992
Turcot's syndrome. Flow cytometric analysis. 1991
Intracerebral Hodgkin's disease in a human immunodeficiency virus-seropositive patient. 1991
Primary central nervous system lymphoma as a secondary malignancy. 1991
Massive pulmonary hemangiopericytoma. An innovative approach to evaluation and treatment. 1989
Carboplatin-associated thrombotic microangiopathic hemolytic anemia. 1989
Conservative treatment of distal rectal cancer by local excision. 1989
Diffuse cystic angiomatosis of the breast. 1988
Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil. 1988
Megakaryoblastic transformation of chronic granulocytic leukemia. 1987
A complication of prolonged infusional chemotherapy masquerading as a bone metastasis in a patient with colorectal carcinoma. 1987
Lymphangiosarcoma associated with chronic filarial lymphedema. 1987
Monitoring intravesical bacillus Calmette-Guerin treatment of superficial bladder carcinoma by serial flow cytometry. 1986
Intrapulmonary presentation of extraskeletal myxoid chondrosarcoma of the extremity. Report of two cases. 1986
Chronic renal failure: a significant risk factor in the development of acquired renal cysts and renal cell carcinoma. Case reports and review of the literature. 1986
Familial neuroblastoma. Case reports, literature review, and etiologic considerations. 1986
Consecutive lymphoma with monoclonal gammopathy in a married couple. 1986
Non-Hodgkin's lymphoma associated with pregnancy. A report of six cases, with a review of the literature. 1985
Teratoma with malignant transformation in germ cell tumors in men. 1985
Bowel perforation during initial treatment for childhood non-Hodgkin's lymphoma. 1985
A distinctive cutaneous malignant neoplasm expressing the Langerhans cell phenotype. Synchronous occurrence with B-chronic lymphocytic leukemia. 1985
Endoscopic diagnosis and treatment of upper-tract urothelial tumors. A preliminary report. 1985
Multiple nevoid basal cell carcinoma syndrome and Hodgkin's disease. 1984
Primary hepatic or hepatosplenic non-Hodgkin's lymphoma in children. 1983
Acute myocardial infarction with normal coronary arteriogram after mantle field radiation therapy for Hodgkin's disease. 1983
Plasmapheresis in a patient with angioimmunoblastic lymphadenopathy. Improvement in clinical and immunologic abnormalities. 1983
Granulomatous infections complicating hairy cell leukemia. 1982
Angioimmunoblastic lymphadenopathy: clinical spectrum of disease. 1981
Malignant thymoma: renal metastases responding to cis-platinum. 1981
Combined Pneumocystis carinii and Nocardia asteroides pneumonitis in a patient with an ACTH-producing carcinoid. 1981
Spontaneous regression of pulmonary metastases from transitional cell carcinoma. 1980
Phase II trial of neocarzinostatin in patients with bladder and prostatic cancer: toxicity of a five-day iv bolus schedule. 1980
Microangiopathic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouracil. 1980
Bone marrow transplantation for the therapy of refractory adult T cell acute lymphoblastic leukemia. 1980
Small-cell carcinoma of the esophagus: treatment by chemotherapy alone. 1980
Acclerated growth of testicular cancer after cytoreductive surgery. 1980
Therapy for metastatic colorectal carcinoma with a combination of methyl-CCNU, 5-fluorouracil vincristine and streptozotocin (MOF-Strep). 1980
Surgical repair of esophagobronchial fistula following successful treatment of Hodgkin's disease. 1979
Philadelphia chromosome positive chronic myelogenous leukemia developing in a patient with acute lymphoblastic leukemia. 1979
Nodular lymphocytic lymphoma eventuating into diffuse histiocytic lymphoma: immunoperoxidase demonstration of monoclonality. 1979
Factors associated with prolonged survival in chronic myeloid leukemia. 1978
Immunoblastic lymphadenopathy and adenocarcinoma of the pancreas: a case report. 1978
Iatrogenic lactic acidosis: association with hypertonic glucose administration in a patient with cancer. 1978
Incidental discovery at radical mastectomy of inapparent Hodgkin's disease in long term survivors. 1978
Pleomorphic reticulum cell sarcoma, monoclonal gammopathy and amyloidosis: an immunoperoxidase study. 1978
Relationship of a T-lymphocyte marker to phase of cell cycle and morphology of leukemic cells. 1977
Hodgkin's disease and granulomatous angiitis of the central nervous system. 1976
Methotrexate pneumonitis induced by intrathecal methotrexate therapy: a case report with pharmacokinetic data. 1976
Thymoma and chronic myelogenous leukemia: a case report. 1976
Treatment of Bowen's disease with topical dinitrochlorobenzene and 5-fluorouracil. 1976
Proliferative kinetics of central nervous system (CNS) leukemia. 1975
Documented hyperparathyroidism of thirty-six years' duration. 1975
Acute leukemia presenting as laryngeal obstruction. 1974
Cell cycle changes in ovarian cancer after arabinosylcytosine. 1974
Effects of an educational physical activity intervention in young women with newly diagnosed breast cancer: Findings from the Young and Strong Study.. 129. 2023
The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.. 129. 2023
What happens in the long term: Uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing.. 128. 2022
Disparities in cancer genetics care by race/ethnicity among pan-cancer patients with pathogenic germline variants.. 128. 2022
Association between immigrant status and advanced cancer patients' location and quality of death.. 128. 2022
Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors.. 128. 2022
"Is it cancer or not?" A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ.. 128. 2022
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.. 128. 2021
Transoral robotic surgery adoption and safety in treatment of oropharyngeal cancers.. 128. 2021
Have urinary function outcomes after radical prostatectomy improved over the past decade?. 128. 2021
Trajectories of fear of cancer recurrence in young breast cancer survivors.. 128. 2021
Social determinants of health and cancer mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study.. 128. 2021
Economic distress, financial toxicity, and medical cost-coping in young adult cancer survivors during the COVID-19 pandemic: Findings from an online sample.. 127. 2021
Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.. 127. 2021
Treatment patterns and survival in patients with early-onset pancreatic cancer.. 127. 2021
Financial toxicity, mental health, and gynecologic cancer treatment: The effect of the COVID-19 pandemic among low-income women in New York City.. 127. 2021
Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors.. 127. 2021
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).. 127. 2021
Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.. 127. 2021
Geospatial access predicts cancer stage at presentation and outcomes for patients with breast cancer in southwest Nigeria: A population-based study.. 127. 2020
Racial disparities in patients with coronavirus disease 2019 infection and gynecologic malignancy.. 127. 2020
Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer.. 127. 2020
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.. 126. 2020
Clinical implications of drug-induced liver injury in early-phase oncology clinical trials.. 126. 2020
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.. 126. 2020
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes.. 126. 2020
Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.. 126. 2020
The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer.. 126. 2020
Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.. 126. 2020
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.. 126. 2020
Changes in prostate-specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men.. 126. 2020
11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood.. 126. 2020
Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial.. 126. 2020
Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance.. 126. 2020
Differences in ambulatory care fragmentation between cancer survivors and noncancer controls.. 126. 2020
Distant metastasis of salivary gland cancer: Incidence, management, and outcomes.. 126. 2020
Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies.. 126. 2020
Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings.. 126. 2020
Diabetes care management patterns before and after a cancer diagnosis: A SEER-Medicare matched cohort study.. 126. 2020
Genomic and clinical characterization of stromal infiltration markers in prostate cancer.. 126. 2020
The experience of hearing loss in adult survivors of childhood and young adult cancer: A qualitative study.. 126. 2020
Human papillomavirus and survival of patients with sinonasal squamous cell carcinoma.. 126. 2019
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.. 126. 2019
Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer.. 126. 2019
Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis.. 126. 2019
"My doctor says the cancer is worse, but I believe in miracles"-When religious belief in miracles diminishes the impact of news of cancer progression on change in prognostic understanding.. 126. 2019
Is screening for psychosocial risk factors associated with mental health care in older adults with cancer undergoing surgery?. 126. 2019
Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.. 126. 2019
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.. 126. 2019
Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.. 125. 2019
Obesity and breast cancer screening: Cross-sectional survey results from the behavioral risk factor surveillance system.. 125. 2019
Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer.. 125. 2019
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).. 125. 2019
Association between advanced cancer patient-caregiver agreement regarding prognosis and hospice enrollment.. 125. 2019
Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.. 125. 2019
Impact of exercise on psychological burden in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.. 125. 2019
Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms.. 125. 2019
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷ Lu-J591) for metastatic castration-resistant prostate cancer.. 125. 2019
A scale to assess religious beliefs in end-of-life medical care.. 125. 2019
A randomized study to improve care for young women with breast cancer at community and academic medical oncology practices in the United States: The Young and Strong study.. 125. 2019
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.. 125. 2019
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.. 125. 2019
Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes.. 125. 2019
Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. 125. 2019
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.. 125. 2018
Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.. 125. 2018
Survival, local control, and health-related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study.. 125. 2018
Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.. 125. 2018
Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations.. 125. 2018
Estimating child mortality associated with maternal mortality from breast and cervical cancer.. 125. 2018
Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: A cluster randomized controlled trial.. 124. 2018
Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.. 124. 2018
Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.. 124. 2018
The intersection of financial toxicity and family building in young adult cancer survivors.. 124. 2018
Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: A randomized controlled trial in patients with advanced cancer.. 124. 2018
Symptom and function profiles of men with localized prostate cancer.. 124. 2018
A symptom-based model to predict colorectal cancer in low-resource countries: Results from a prospective study of patients at high risk for colorectal cancer.. 124. 2018
Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.. 124. 2018
Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial.. 124. 2018
Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life.. 124. 2018
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.. 124. 2018
Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.. 124. 2018
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.. 124. 2018
Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. 124. 2017
Travel distance and stereotactic body radiotherapy for localized prostate cancer.. 124. 2017
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.. 124. 2017
Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness.. 123. 2017
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.. 124. 2017
Comparison of recommendations for screening mammography using CISNET models.. 123. 2017
A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.. 123. 2017
Preventable and mitigable adverse events in cancer care: Measuring risk and harm across the continuum.. 123. 2017
Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.. 123. 2017
Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.. 123. 2017
Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.. 123. 2017
Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation.. 123. 2017
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.. 123. 2017
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.. 123. 2017
Androgen receptor-positive, triple-negative breast cancer.. 123. 2017
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.. 123. 2017
Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma.. 123. 2017
Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?. 123. 2017
Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study.. 123. 2017
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.. 123. 2017
Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.. 123. 2017
Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract.. 123. 2017
Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.. 123. 2017
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.. 123. 2017
A pilot randomized controlled trial of cognitive bias modification to reduce fear of breast cancer recurrence.. 123. 2017
Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.. 123. 2016
The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era.. 123. 2016
A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.. 123. 2016
Clinical and genetic determinants of ovarian metastases from colorectal cancer.. 123. 2016
An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.. 123. 2016
Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.. 123. 2016
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).. 123. 2016
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.. 122. 2016
Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.. 123. 2016
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).. 122. 2016
Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods.. 123. 2016
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.. 122. 2016
The efficacy of anti-PD-1 agents in acral and mucosal melanoma.. 122. 2016
Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy.. 122. 2016
Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.. 123. 2016
Patient function, long-term survival, and use of surgery in patients with kidney cancer.. 122. 2016
Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study.. 122. 2016
White adipose tissue inflammation and cancer-specific survival in patients with squamous cell carcinoma of the oral tongue.. 122. 2016
Genomic characterization of response to chemoradiation in urothelial bladder cancer.. 122. 2016
Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.. 122. 2016
Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance).. 122. 2016
National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. 122. 2016
Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.. 122. 2016
Breast intraductal papillomas without atypia in radiologic-pathologic concordant core-needle biopsies: Rate of upgrade to carcinoma at excision.. 122. 2016
Patient experience and quality of urologic cancer surgery in US hospitals.. 122. 2016
Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.. 122. 2016
Second-opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care.. 122. 2016
Young adult female cancer survivors' unmet information needs and reproductive concerns contribute to decisional conflict regarding posttreatment fertility preservation.. 122. 2016
Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.. 122. 2016
Accuracy of advanced cancer patients' life expectancy estimates: The role of race and source of life expectancy information.. 122. 2016
Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research.. 122. 2016
Impact of end-of-life discussions on the reduction of Latino/non-Latino disparities in do-not-resuscitate order completion.. 122. 2016
Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base.. 122. 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.. 122. 2016
Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.. 122. 2016
Preoperative experience for public hospital patients with gynecologic cancer: Do structural barriers widen the gap?. 122. 2016
Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.. 122. 2016
Chronic medical conditions in adult survivors of retinoblastoma: Results of the Retinoblastoma Survivor Study.. 122. 2016
Impact of vision loss among survivors of childhood central nervous system astroglial tumors.. 122. 2016
Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.. 122. 2016
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.. 122. 2015
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.. 122. 2015
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.. 122. 2015
Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses' Health Studies.. 122. 2015
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.. 122. 2015
Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.. 122. 2015
Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients.. 122. 2015
The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base.. 122. 2015
Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.. 122. 2015
Identification of germline genetic mutations in patients with pancreatic cancer.. 121. 2015
Extent of resection and overall survival for patients with atypical and malignant meningioma.. 121. 2015
Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.. 121. 2015
Population-based assessment of determining predictors for quality of prostate cancer surveillance.. 121. 2015
Cost-effectiveness analysis of papillary thyroid cancer surveillance.. 121. 2015
Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT.. 121. 2015
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.. 121. 2015
Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.. 121. 2015
Disparities in survival by insurance status in patients with Hodgkin lymphoma.. 121. 2015
The lasting impact of the therapeutic alliance: Patient-oncologist alliance as a predictor of caregiver bereavement adjustment.. 121. 2015
Do attitudes and beliefs regarding complementary and alternative medicine impact its use among patients with cancer? A cross-sectional survey.. 121. 2015
Male-female patient differences in the association between end-of-life discussions and receipt of intensive care near death.. 121. 2015
The effect of oncologists' exercise recommendations on the level of exercise and quality of life in survivors of breast and colorectal cancer: A randomized controlled trial.. 121. 2015
Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.. 121. 2015
Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.. 121. 2015
Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis.. 121. 2015
Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates.. 121. 2015
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.. 121. 2014
The effects of cancer and racial disparities in health-related quality of life among older Americans: a case-control, population-based study.. 121. 2014
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.. 121. 2014
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.. 121. 2014
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project.. 121. 2014
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).. 121. 2014
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.. 121. 2014
A mixed-methods examination of communication between oncologists and primary care providers among primary care physicians in underserved communities.. 121. 2014
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.. 121. 2014
Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group.. 121. 2014
Electronic cigarette use among patients with cancer: characteristics of electronic cigarette users and their smoking cessation outcomes.. 120. 2014
Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.. 121. 2014
Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma.. 121. 2014
KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.. 120. 2014
End-of-life treatment preferences: a key to reducing ethnic/racial disparities in advance care planning?. 120. 2014
US lung cancer trends by histologic type.. 120. 2014
Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma.. 120. 2014
Does adjuvant radiotherapy benefit patients with diffuse-type gastric cancer? Results from the Surveillance, Epidemiology, and End Results database.. 120. 2014
Suicidal ideation in prostate cancer survivors: understanding the role of physical and psychological health outcomes.. 120. 2014
Patient-oncologist alliance as protection against suicidal ideation in young adults with advanced cancer.. 120. 2014
Treatment-related amenorrhea and sexual functioning in young breast cancer survivors.. 120. 2014
Infections among long-term survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study.. 120. 2014
Daughters and Mothers Against Breast Cancer (DAMES): main outcomes of a randomized controlled trial of weight loss in overweight mothers with breast cancer and their overweight daughters.. 120. 2014
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.. 120. 2014
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.. 120. 2014
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.. 120. 2014
Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.. 120. 2014
The prognosis of N2b and N2c lymph node disease in oral squamous cell carcinoma is determined by the number of metastatic lymph nodes rather than laterality: evidence to support a revision of the American Joint Committee on Cancer staging system.. 120. 2014
Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.. 120. 2014
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.. 120. 2014
Causes of death in long-term survivors of head and neck cancer.. 120. 2014
Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period.. 120. 2014
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.. 120. 2014
Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue.. 120. 2014
Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710.. 120. 2014
Distribution and trends of hematology and oncology research in Latin America: A decade of uncertainty.. 120. 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.. 120. 2013
Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective.. 120. 2013
The end-of-life experience: modifiable predictors of caregivers' bereavement adjustment.. 120. 2013
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.. 120. 2013
Reducing time-to-treatment in underserved Latinas with breast cancer: the Six Cities Study.. 120. 2013
Breast cancer presentation and diagnostic delays in young women.. 120. 2013
Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for patients with esophageal cancer: a SEER-Medicare analysis.. 120. 2013
Nomograms for preoperative prediction of prognosis in patients with oral cavity squamous cell carcinoma.. 120. 2013
Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group.. 120. 2013
Suicide ideation and associated mortality in adult survivors of childhood cancer.. 120. 2013
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.. 119. 2013
Improvement in survival of patients with oral cavity squamous cell carcinoma: An international collaborative study.. 119. 2013
Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.. 119. 2013
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.. 119. 2013
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials.. 119. 2013
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.. 119. 2013
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.. 119. 2013
Addressing overtreatment in breast cancer: The doctors' dilemma.. 119. 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.. 119. 2013
Dynamic prognostication using conditional survival estimates.. 119. 2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).. 119. 2013
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.. 119. 2013
The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome.. 119. 2013
Intensity-modulated radiotherapy (IMRT) in pediatric low-grade glioma.. 119. 2013
Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.. 119. 2013
Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.. 119. 2013
Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older.. 119. 2013
Expression of androgen receptor and its phosphorylated forms in breast cancer progression.. 119. 2013
Acupuncture in the treatment of upper-limb lymphedema: results of a pilot study.. 119. 2013
Health care-associated infections after major cancer surgery: temporal trends, patterns of care, and effect on mortality.. 119. 2013
External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.. 119. 2013
Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer.. 119. 2013
A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.. 119. 2013
Association between exercise and primary incidence of prostate cancer: does race matter?. 119. 2013
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).. 119. 2013
A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas.. 119. 2013
Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients.. 119. 2012
Examining whether lung screening changes risk perceptions: National Lung Screening Trial participants at 1-year follow-up.. 119. 2012
Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trial.. 119. 2012
Navigating Latinas with breast screen abnormalities to diagnosis: the Six Cities Study.. 119. 2012
Implementing a breast cancer registry and treatment plan/summary program in clinical practice: a pilot program.. 119. 2012
Patient perspectives on breast cancer treatment plan and summary documents in community oncology care: a pilot program.. 119. 2012
Long-term regional control and survival in patients with "low-risk," early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation: the importance of tumor thickness.. 119. 2012
Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.. 119. 2012
ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma.. 119. 2012
Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision.. 119. 2012
Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer.. 119. 2012
Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma.. 119. 2012
Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial.. 119. 2012
Elderly patients with colon cancer have unique tumor characteristics and poor survival.. 119. 2012
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.. 119. 2012
Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women.. 119. 2012
Determining the impact of US mammography screening guidelines on patient survival in a predominantly African American population treated in a public hospital during 2008.. 119. 2012
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.. 119. 2012
Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences.. 118. 2012
Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.. 119. 2012
Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy.. 118. 2012
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.. 118. 2012
Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma.. 118. 2012
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.. 118. 2012
Fractures among long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.. 118. 2012
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.. 118. 2012
A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.. 118. 2012
Measuring psychosocial distress and parenting concerns among adults with cancer: the Parenting Concerns Questionnaire.. 118. 2012
Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer.. 118. 2012
Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older.. 118. 2012
Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.. 118. 2012
Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis.. 118. 2012
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.. 118. 2012
Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors.. 118. 2012
A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer.. 118. 2012
Costs and trends in pancreatic cancer treatment.. 118. 2012
Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy.. 118. 2012
Leapfrog volume thresholds and perioperative complications after radical prostatectomy.. 118. 2012
Psychometric validation of the Female Sexual Function Index (FSFI) in cancer survivors.. 118. 2012
Use of complementary medications among older adults with cancer.. 118. 2012
Disparities in access to care at high-volume institutions for uro-oncologic procedures.. 118. 2012
Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study.. 118. 2012
Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.. 118. 2012
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.. 118. 2011
Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.. 118. 2011
Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma.. 118. 2011
Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973-2008.. 118. 2011
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.. 118. 2011
Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer.. 118. 2011
Durable remission with salvage second autotransplants in patients with multiple myeloma.. 118. 2011
Young women with family history of breast cancer and their risk factors for benign breast disease.. 118. 2011
Androgen deprivation and thromboembolic events in men with prostate cancer.. 118. 2011
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study.. 118. 2011
Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma.. 118. 2011
Costs of medical care after open or minimally invasive prostate cancer surgery: a population-based analysis.. 118. 2011
Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma.. 118. 2011
Patient satisfaction and health-related quality of life after autologous tissue breast reconstruction: a prospective analysis of early postoperative outcomes.. 118. 2011
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response.. 118. 2011
Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment.. 118. 2011
A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.. 118. 2011
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.. 118. 2011
Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer.. 118. 2011
Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.. 118. 2011
The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy.. 118. 2011
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.. 118. 2011
Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation.. 118. 2011
Long-term outcomes in breast cancer patients undergoing immediate 2-stage expander/implant reconstruction and postmastectomy radiation.. 118. 2011
Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States.. 118. 2011
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.. 118. 2011
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.. 118. 2011
Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.. 118. 2011
Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection.. 118. 2011
Morbidity and mortality of radical prostatectomy differs by insurance status.. 118. 2011
Return to work in low-income Latina and non-Latina white breast cancer survivors: a 3-year longitudinal study.. 118. 2011
Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States.. 118. 2011
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.. 118. 2011
Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809.. 117. 2011
A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma.. 118. 2011
Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma: relevance of the seventh edition American Joint Committee on Cancer Staging Manual revision.. 118. 2011
Early stage squamous cell cancer of the oral tongue--clinicopathologic features affecting outcome.. 118. 2011
The enigma of myxofibrosarcoma of the extremity.. 118. 2011
Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303).. 118. 2011
Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.. 117. 2011
Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer.. 117. 2011
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.. 117. 2011
Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.. 118. 2011
Research challenges in adolescent and young adult cancer survivor research.. 117. 2011
The cancer is over, now what?: Understanding risk, changing outcomes.. 117. 2011
A Surveillance, Epidemiology, and End Results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends.. 117. 2011
Support of cancer patients' spiritual needs and associations with medical care costs at the end of life.. 117. 2011
Patients rate physician communication about lung cancer.. 117. 2011
Reirradiation for recurrent medulloblastoma.. 117. 2011
Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy.. 117. 2011
Soft tissue sarcoma diagnosed subsequent to lymphoma is associated with prior radiotherapy and decreased survival.. 117. 2011
Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.. 117. 2011
Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy.. 117. 2011
Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.. 117. 2011
Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: a survival analysis.. 117. 2011
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.. 117. 2011
Utilization and expense of adjuvant cancer therapies following radical prostatectomy.. 117. 2011
Conditional survival predictions after surgery for patients with penile carcinoma.. 117. 2011
Prospective study of growth and development in older girls and risk of benign breast disease in young women.. 117. 2011
Local control comparison of adjuvant brachytherapy to intensity-modulated radiotherapy in primary high-grade sarcoma of the extremity.. 117. 2011
Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis.. 117. 2011
Higher population-based incidence rates of triple-negative breast cancer among young African-American women : Implications for breast cancer screening recommendations.. 117. 2011
Studying cancer in minorities: a look at the numbers.. 117. 2011
Clinical outcomes for patients with soft tissue sarcoma of the hand.. 117. 2011
Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study.. 117. 2010
Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy.. 117. 2010
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.. 116. 2010
Evaluation of lymph node counts in primary retroperitoneal lymph node dissection.. 116. 2010
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.. 117. 2010
Addition of pamidronate to chemotherapy for the treatment of osteosarcoma.. 117. 2010
Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival.. 117. 2010
Patient satisfaction with postmastectomy breast reconstruction: a comparison of saline and silicone implants.. 116. 2010
Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.. 117. 2010
Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer.. 117. 2010
Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement.. 117. 2010
African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study.. 116. 2010
Evaluation of a breast cancer risk prediction model expanded to include category of prior benign breast disease lesion.. 116. 2010
Methylphenidate for fatigue in ambulatory men with prostate cancer.. 116. 2010
Expanding colorectal cancer screening among minority women.. 117. 2010
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.. 117. 2010
Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas.. 116. 2010
Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer.. 116. 2010
A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.. 117. 2010
Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study.. 117. 2010
Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience.. 116. 2010
Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography.. 116. 2010
Influence of patients' preferences and treatment site on cancer patients' end-of-life care.. 116. 2010
Craniofacial resection for malignant tumors involving the skull base in the elderly: an international collaborative study.. 117. 2010
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.. 117. 2010
Increasing incidence of rectal cancer in patients aged younger than 40 years: an analysis of the surveillance, epidemiology, and end results database.. 116. 2010
Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma.. 117. 2010
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.. 116. 2010
Noninvasive imaging with thallium-201 scintigraphy may not correlate with survival in patients with osteosarcoma.. 116. 2010
A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer.. 117. 2010
Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals.. 116. 2010
Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.. 116. 2010
Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogram.. 116. 2010
Highly predictive survival nomogram after upper urinary tract urothelial carcinoma.. 116. 2010
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.. 116. 2010
The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials.. 116. 2010
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.. 116. 2010
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.. 116. 2010
A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score.. 116. 2010
A prospective evaluation of the durability of palliative interventions for patients with metastatic breast cancer.. 116. 2010
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.. 116. 2010
Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study.. 116. 2010
Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma.. 116. 2010
Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study.. 116. 2010
Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4.. 116. 2010
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.. 116. 2010
Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.. 116. 2010
Novel targeted therapies in inflammatory breast cancer.. 116. 2010
Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids.. 116. 2010
Trends in renal tumor surgery delivery within the United States.. 116. 2010
Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor).. 116. 2010
Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size: a new source of bias in morbidity assessment?. 116. 2010
Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.. 116. 2010
Anxiety disorders in advanced cancer patients: correlates and predictors of end-of-life outcomes.. 116. 2010
Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas.. 116. 2010
Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma.. 116. 2010
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.. 116. 2010
Guide for investigators conducting international cancer research involving developing nations.. 116. 2010
Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy.. 116. 2010
Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.. 116. 2010
Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter?. 116. 2010
A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer.. 116. 2010
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.. 116. 2010
Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803.. 116. 2010
Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer.. 116. 2010
Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma.. 116. 2010
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study.. 116. 2010
Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.. 116. 2010
Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.. 116. 2010
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.. 116. 2010
Clinical utility of postchemoradiation endoscopic brush cytology and biopsy in predicting residual esophageal adenocarcinoma.. 117. 2009
Impact of radiation and chemotherapy on risk of dental abnormalities: a report from the Childhood Cancer Survivor Study.. 115. 2009
Lymph node density is a significant predictor of outcome in patients with oral cancer.. 115. 2009
Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective.. 115. 2009
Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach.. 115. 2009
Ethnic disparity in mortality after diagnosis of colorectal cancer among inner city minority New Yorkers.. 115. 2009
Identification of borderline thyroid tumors by gene expression array analysis.. 115. 2009
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.. 115. 2009
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.. 115. 2009
Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma.. 115. 2009
Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma.. 115. 2009
A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years.. 115. 2009
Image-guided ThinPrep Papanicolaou tests and cotesting with high-risk human papillomavirus in women aged 30 years and older in a low-risk private practice population.. 117. 2009
Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials.. 115. 2009
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.. 115. 2009
Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.. 115. 2009
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.. 115. 2009
Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.. 117. 2009
Measuring therapeutic alliance between oncologists and patients with advanced cancer: the Human Connection Scale.. 115. 2009
Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver.. 115. 2009
EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.. 115. 2009
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.. 115. 2009
Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study.. 115. 2009
Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland.. 115. 2009
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.. 115. 2009
p16(INK4A) immunohistochemical staining may be helpful in distinguishing branchial cleft cysts from cystic squamous cell carcinomas originating in the oropharynx.. 117. 2009
Lobule type and subsequent breast cancer risk: results from the Nurses' Health Studies.. 115. 2009
Radical versus partial nephrectomy: effect on overall and noncancer mortality.. 115. 2009
Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000.. 115. 2009
Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy.. 115. 2009
Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.. 115. 2009
Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration.. 115. 2009
Postmastectomy radiotherapy for breast cancer: patterns, correlates, communication, and insights into the decision process.. 115. 2009
Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541.. 115. 2009
Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer.. 115. 2009
Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.. 115. 2009
EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer.. 117. 2009
Reflex UroVysion testing in suspicious urine cytology cases.. 117. 2009
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.. 115. 2009
Hypofractionated stereotactic radiotherapy for the treatment of brain metastases.. 115. 2009
Comparison of models to predict clinical failure after radical prostatectomy.. 115. 2009
Mental health, treatment preferences, advance care planning, location, and quality of death in advanced cancer patients with dependent children.. 115. 2009
Novel agents in myeloma: an exciting saga.. 115. 2009
Survival of distinct Asian groups among colorectal cancer cases in California.. 115. 2009
Influence of compartmental involvement on the patterns of morbidity in soft tissue sarcoma of the thigh.. 115. 2009
Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.. 115. 2009
Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquid-based cervicovaginal material: a pilot study.. 114. 2008
Changes in the presentation of nodular and superficial spreading melanomas over 35 years.. 113. 2008
Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy.. 113. 2008
Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study.. 113. 2008
A prospective feasibility trial to determine the significance of the sentinel node gradient in breast cancer: a predictor of nodal metastasis location.. 113. 2008
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.. 113. 2008
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.. 113. 2008
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.. 113. 2008
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.. 113. 2008
Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?. 113. 2008
Merkel cell carcinoma: histologic features and prognosis.. 113. 2008
Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.. 114. 2008
Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma.. 113. 2008
Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation.. 113. 2008
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.. 113. 2008
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.. 113. 2008
Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel.. 113. 2008
Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme.. 113. 2008
Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.. 113. 2008
Cancer screening practices of adult survivors of retinoblastoma at risk of second cancers.. 113. 2008
High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma.. 113. 2008
Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms.. 113. 2008
Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.. 113. 2008
Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation.. 113. 2008
Survival rates after resection for localized kidney cancer: 1989 to 2004.. 113. 2008
Impact of the more restrictive definition of atypical squamous cells introduced by the 2001 Bethesda System on the sensitivity and specificity of the Papanicolaou test: a 5-year follow-up study of Papanicolaou tests originally interpreted as ASCUS, reclassified according to Bethesda 2001 criteria.. 114. 2008
Cervical cancer in patients infected with the human immunodeficiency virus.. 112. 2008
Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy.. 112. 2008
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.. 112. 2008
Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy.. 112. 2008
Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up.. 112. 2008
Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer.. 112. 2008
Peace, Equanimity, and Acceptance in the Cancer Experience (PEACE): validation of a scale to assess acceptance and struggle with terminal illness.. 112. 2008
Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.. 112. 2008
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy.. 112. 2008
Experience with 31 sentinel lymph node biopsies for sarcomas and carcinomas in pediatric patients.. 112. 2008
Prognostic significance of HER-2 status in women with inflammatory breast cancer.. 112. 2008
Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study.. 112. 2008
Diagnostic challenges of metastatic spindle cell melanoma on fine-needle aspiration specimens.. 114. 2008
Correlates of patient satisfaction and provider trust after breast-conserving surgery.. 112. 2008
Negative influence of changing biopsy practice patterns on the predictive value of prostate-specific antigen for cancer detection on prostate biopsy.. 112. 2008
Proxy perspectives regarding end-of-life care for persons with cancer.. 112. 2008
Changing indications for surgery in patients with stage IV breast cancer: a current perspective.. 112. 2008
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.. 112. 2008
Symptom burden after autologous stem cell transplantation for multiple myeloma.. 112. 2008
Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy?. 112. 2008
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.. 112. 2008
Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium.. 112. 2008
Cytologic findings after fertility-sparing radical trachelectomy.. 114. 2008
The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.. 112. 2008
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).. 112. 2008
Understanding the impact of breast reconstruction on the surgical decision-making process for breast cancer.. 112. 2008
Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.. 112. 2008
Bcl-6 predicts improved prognosis in primary central nervous system lymphoma.. 112. 2008
Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent.. 112. 2008
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.. 110. 2007
Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma.. 110. 2007
Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis.. 110. 2007
Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung.. 110. 2007
Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging.. 110. 2007
Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration.. 110. 2007
Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.. 110. 2007
Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study.. 110. 2007
Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation.. 110. 2007
Patterns of treatment in older adults with primary central nervous system lymphoma.. 110. 2007
Analysis of prognostic factors in 146 patients with anterior skull base sarcoma: an international collaborative study.. 110. 2007
Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma.. 110. 2007
Liquid-based Papanicolaou test (SurePath) interpretations before histologic diagnosis of endometrial hyperplasias and carcinomas: study of 272 cases classified by the 2001 Bethesda system.. 111. 2007
Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer.. 110. 2007
Effects of presurgical exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for malignant lung lesions.. 110. 2007
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.. 110. 2007
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.. 110. 2007
Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis?. 110. 2007
Hepatic metastasectomy in children.. 109. 2007
Correlates of referral practices of general surgeons to plastic surgeons for mastectomy reconstruction.. 109. 2007
Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma.. 109. 2007
Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis.. 109. 2007
Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943.. 109. 2007
Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells.. 109. 2007
Management of primary liver sarcomas.. 109. 2007
Survivin expression is associated with bladder cancer presence, stage, progression, and mortality.. 109. 2007
Cytology of desmoplastic small round-cell tumor: comparison of pre- and post-chemotherapy fine-needle aspiration biopsies.. 111. 2007
Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.. 109. 2007
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.. 109. 2007
Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.. 109. 2007
Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.. 109. 2007
EphA2 overexpression is associated with angiogenesis in ovarian cancer.. 109. 2007
Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study.. 109. 2007
A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.. 107. 2006
Distress, psychiatric syndromes, and impairment of function in women with newly diagnosed breast cancer.. 107. 2006
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.. 107. 2006
Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression.. 107. 2006
Treatment outcome for metastatic papillary renal cell carcinoma patients.. 107. 2006
Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board.. 107. 2006
Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?. 107. 2006
Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study.. 107. 2006
Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer.. 107. 2006
Grading follicular lymphomas in fine-needle aspiration biopsies: the role of ThinPrep slides and flow cytometry.. 108. 2006
New York City's immigrant minorities. Reducing cancer health disparities.. 107. 2006
Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma.. 107. 2006
Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis.. 107. 2006
Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas: changing the paradigms of treatments?. 107. 2006
Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival.. 107. 2006
Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis.. 107. 2006
Treatment of metastatic sarcoma to the liver with bland embolization.. 107. 2006
Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity.. 107. 2006
The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study.. 107. 2006
A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach.. 107. 2006
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.. 107. 2006
Fine-needle aspiration cytology of mammary adenomyoepithelioma: a study of 12 patients.. 108. 2006
Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.. 107. 2006
Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha.. 107. 2006
A midpoint assessment of the American Cancer Society challenge goal to halve the U.S. cancer mortality rates between the years 1990 and 2015.. 107. 2006
Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.. 107. 2006
The effect of postprostatectomy external beam radiotherapy on quality of life: results from the Cancer of the Prostate Strategic Urologic Research Endeavor.. 107. 2006
Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.. 106. 2006
Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients.. 106. 2006
Selecting patients for breast-conserving therapy: the importance of lobular histology.. 106. 2006
Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy.. 106. 2006
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.. 106. 2006
Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.. 106. 2006
Particle embolization of recurrent hepatocellular carcinoma after hepatectomy.. 106. 2006
Patterns of exercise across the cancer trajectory in brain tumor patients.. 106. 2006
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.. 106. 2006
Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa.. 106. 2006
Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases.. 106. 2006
Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.. 106. 2006
Outcome of patients with fibrolamellar hepatocellular carcinoma.. 106. 2006
Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients.. 106. 2006
Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma.. 106. 2006
Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.. 106. 2006
Implications for clinical staging of metastatic cutaneous squamous carcinoma of the head and neck based on a multicenter study of treatment outcomes.. 106. 2006
Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.. 106. 2006
Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma.. 106. 2006
Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma.. 106. 2006
Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival.. 106. 2006
Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence?. 106. 2006
Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells.. 106. 2006
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.. 106. 2006
Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma.. 106. 2006
Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.. 106. 2006
Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee.. 106. 2006
Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study.. 104. 2005
Correlates of breast reconstruction: results from a population-based study.. 104. 2005
Long-term outcomes of adult survivors of childhood cancer.. 104. 2005
Salvage temozolomide for prior temozolomide responders.. 104. 2005
Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma.. 104. 2005
Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis.. 104. 2005
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.. 104. 2005
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.. 104. 2005
Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience.. 104. 2005
Developing a cancer-specific geriatric assessment: a feasibility study.. 104. 2005
Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma.. 104. 2005
Surgeon perspectives about local therapy for breast carcinoma.. 104. 2005
Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.. 104. 2005
Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.. 104. 2005
Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.. 104. 2005
The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999.. 104. 2005
Significance of benign endometrial cells in papanicolaou tests from women aged >or=40 years.. 105. 2005
The utility of B72.3, carcinoembryonic antigen, and Leu M-1 in cell blocks: an adjunct to fine-needle aspiration diagnosis of bronchioloalveolar carcinoma of the lung.. 105. 2005
Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.. 104. 2005
Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence.. 104. 2005
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy.. 104. 2005
Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up.. 104. 2005
Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters.. 103. 2005
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.. 103. 2005
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.. 103. 2005
Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy.. 103. 2005
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.. 103. 2005
Postoperative complications of salvage total laryngectomy.. 103. 2005
Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.. 103. 2005
Survivors of childhood cancer and their guardians.. 103. 2005
Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study.. 103. 2005
Body mass index in long-term adult survivors of childhood cancer: a report of the Childhood Cancer Survivor Study.. 103. 2005
Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women?. 103. 2005
The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.. 103. 2005
Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma.. 103. 2005
Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma.. 103. 2005
Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma.. 103. 2005
Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system.. 103. 2005
Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.. 103. 2005
Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study.. 101. 2004
A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy.. 101. 2004
Multiple primary soft tissue sarcomas.. 101. 2004
Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.. 101. 2004
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.. 101. 2004
Validation of the postoperative nomogram for 12-year sarcoma-specific mortality.. 101. 2004
Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study.. 102. 2004
Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.. 101. 2004
Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.. 101. 2004
Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma.. 101. 2004
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.. 101. 2004
The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer.. 101. 2004
Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.. 101. 2004
An academic health center cost analysis of screening mammography: creating a financially viable service.. 101. 2004
Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy.. 101. 2004
Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma.. 101. 2004
The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.. 101. 2004
The utility of p16INK4a and Ki-67 staining on cell blocks prepared from residual thin-layer cervicovaginal material.. 102. 2004
Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.. 100. 2004
The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy.. 100. 2004
Pathologic evaluation of radical cystectomy specimens: a cooperative group report.. 100. 2004
The development of interval breast malignancies in patients with BRCA mutations.. 100. 2004
Acceptance of tamoxifen chemoprevention by physicians and women at risk.. 100. 2004
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.. 100. 2004
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma.. 100. 2004
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.. 100. 2004
Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors.. 100. 2004
Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or procedural artifact?. 100. 2004
Survivin expression is associated with features of biologically aggressive prostate carcinoma.. 100. 2004
A clinically comprehensive ethical framework for offering and recommending cancer treatment before and during pregnancy.. 100. 2004
Music therapy for mood disturbance during hospitalization for autologous stem cell transplantation: a randomized controlled trial.. 98. 2003
Is endometrial carcinoma intrinsically more aggressive in elderly patients?. 98. 2003
Ductal lavage in patients undergoing mastectomy for mammary carcinoma: a correlative study.. 98. 2003
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.. 98. 2003
The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States.. 98. 2003
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies.. 98. 2003
Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials.. 98. 2003
Craniofacial surgery for malignant skull base tumors: report of an international collaborative study.. 98. 2003
Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.. 98. 2003
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.. 98. 2003
Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy.. 98. 2003
Comparison of ThinPrep and conventional smears in detecting carcinoma in bile duct brushings.. 99. 2003
Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy.. 98. 2003
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.. 98. 2003
Probably benign lesions at breast magnetic resonance imaging: preliminary experience in high-risk women.. 98. 2003
Symptoms and signs of primary melanoma: important indicators of Breslow depth.. 98. 2003
Evidence of a preferred molecular pathway in patients with synchronous colorectal cancer.. 98. 2003
Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma.. 98. 2003
The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer.. 97. 2003
Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence.. 97. 2003
Conservative management of Paget disease of the breast with radiotherapy: 10- and 15-year results.. 97. 2003
Sentinel lymph node analysis in patients with sweat gland carcinoma.. 97. 2003
Nipple aspirate fluid cytology in breast carcinoma.. 99. 2003
Can patient selection for bladder preservation be based on response to chemotherapy?. 97. 2003
Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations.. 97. 2003
Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs.. 97. 2003
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.. 97. 2003
Overdiagnosis in chest radiographic screening for lung carcinoma: frequency.. 97. 2003
The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.. 99. 2003
Compliance with breast-conservation standards for patients with early-stage breast carcinoma.. 97. 2003
Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.. 97. 2003
Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study.. 97. 2003
Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.. 97. 2003
Increasing the pool of academically oriented African-American medical and surgical oncologists.. 97. 2003
Long-term results of three-dimensional conformal radiation therapy for patients with rhabdomyosarcoma.. 97. 2003
Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.. 95. 2002
Pathologic review of the Mayo Lung Project cancers [corrected]. Is there a case for misdiagnosis or overdiagnosis of lung carcinoma in the screened group?. 95. 2002
Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study.. 95. 2002
An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up.. 95. 2002
Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma.. 95. 2002
Hepatic intraductal oncocytic papillary carcinoma.. 95. 2002
Conventional hemangiopericytoma: modern analysis of outcome.. 95. 2002
Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience.. 95. 2002
Improved outcomes in patients with osteogenic sarcoma of the head and neck.. 95. 2002
Strategies for improving melanoma education and screening for men age >or= 50 years: findings from the American Academy of Dermatological National Skin Cancer Sreening Program.. 95. 2002
Chronic neuroblastoma.. 95. 2002
Factors that influence surgical choices in women with breast carcinoma.. 95. 2002
Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.. 95. 2002
Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy.. 95. 2002
A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.. 95. 2002
Pathologic evaluation of radical cystectomy specimens.. 95. 2002
The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma.. 95. 2002
Carcinoma detection at the breast examination center of Harlem.. 95. 2002
Ethnicity related differences in the survival of young breast carcinoma patients.. 95. 2002
The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease.. 95. 2002
High-grade gliomas in patients with prior systemic malignancies.. 94. 2002
Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.. 94. 2002
Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma.. 94. 2002
Soft tissue sarcoma brain metastases. Prevalence in a cohort of 3829 patients.. 94. 2002
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.. 94. 2002
Classification of benign endometrial glandular cells in cervical smears from postmenopausal women.. 96. 2002
Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors.. 94. 2002
Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma.. 94. 2002
Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples.. 96. 2002
Abnormalities of chromosome bands 15q13-15 in childhood acute lymphoblastic leukemia.. 94. 2002
Clinicopathologic correlates of solitary fibrous tumors.. 94. 2002
Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.. 94. 2002
HER-2 profiling and targeting in prostate carcinoma.. 94. 2002
Rationales, evidence, and design considerations for fractionated radioimmunotherapy.. 94. 2002
Results of the Lynn Sage Second-Opinion Program for local therapy in patients with breast carcinoma. Changes in management and determinants of where care is delivered.. 94. 2002
Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients.. 94. 2002
Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.. 94. 2002
Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.. 92. 2001
Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma.. 92. 2001
Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity.. 92. 2001
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma.. 92. 2001
Immunohistochemical analysis of sentinel lymph nodes from patients with Merkel cell carcinoma.. 92. 2001
Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder.. 92. 2001
Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy.. 92. 2001
Cancer rehabilitation into the future.. 92. 2001
GD2 synthase: a new molecular marker for detecting neuroblastoma.. 92. 2001
High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas.. 92. 2001
Early lung cancer action project: initial findings on repeat screenings.. 92. 2001
Diagnosis, pathology, staging, treatment, and outcome of epithelial ovarian neoplasia in patients age < 21 years.. 91. 2001
A case-control study of unilateral and bilateral breast carcinoma patients.. 91. 2001
Impact of breast carcinoma on African-American women: the Detroit experience.. 91. 2001
Should the cytologic diagnosis of "atypical squamous cells of undetermined significance" be qualified? An assessment including comparison between conventional and liquid-based technologies.. 93. 2001
Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma.. 91. 2001
Alternative medicine use worldwide: the International Union Against Cancer survey.. 91. 2001
Peritoneovenous shunting for nongynecologic malignant ascites.. 91. 2001
A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases.. 91. 2001
Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast.. 91. 2001
G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting.. 91. 2001
Clinicopathologic analysis of patients with adult rhabdomyosarcoma.. 91. 2001
Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma.. 91. 2001
Localized non-Hodgkin lymphoma involving the thyroid gland.. 91. 2001
The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma.. 91. 2001
Reducing the cost of diagnosis of breast carcinoma: impact of ultrasound and imaging-guided biopsies on a clinical breast practice.. 91. 2001
Sentinel lymph node biopsy in patients with male breast carcinoma.. 91. 2001
Social support as a buffer to the psychological impact of stressful life events in women with breast cancer.. 91. 2001
Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease.. 91. 2001
A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.. 91. 2001
Imaging-histologic discordance at percutaneous breast biopsy.. 89. 2000
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.. 89. 2000
In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology.. 89. 2000
Is gastric carcinoma different between Japan and the United States?. 89. 2000
Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.. 89. 2000
Successful treatment of metastatic retinoblastoma.. 89. 2000
Outcome of cancer pain consultations.. 89. 2000
Prognostic impact of INK4A deletion in Ewing sarcoma.. 89. 2000
Prognostic impact of P53 status in Ewing sarcoma.. 89. 2000
Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes.. 89. 2000
Patterns of detection in patients with cutaneous melanoma.. 89. 2000
Telomerase activity in B-cell non-Hodgkin lymphoma.. 89. 2000
Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study.. 89. 2000
A comparison of staging systems for localized extremity soft tissue sarcoma.. 88. 2000
Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution.. 88. 2000
Identification and characterization of circulating prostate carcinoma cells.. 88. 2000
The schedule of attitudes toward hastened death: Measuring desire for death in terminally ill cancer patients.. 88. 2000
Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group.. 88. 2000
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.. 88. 2000
A new American Joint Committee on Cancer staging system for cutaneous melanoma.. 88. 2000
Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma.. 88. 2000
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.. 88. 2000
National Cancer Data Base survey of breast cancer management for patients from low income zip codes.. 88. 2000
Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.. 88. 2000
Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection.. 88. 2000
Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder.. 86. 1999
Extremity and trunk desmoid tumors: a multifactorial analysis of outcome.. 86. 1999
Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face.. 86. 1999
Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age.. 86. 1999
The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia.. 86. 1999
Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma.. 86. 1999
Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma.. 86. 1999
Localized male breast carcinoma and family history. An analysis of 142 patients.. 86. 1999
Cytopathology of insular carcinoma of the thyroid.. 87. 1999
The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9.. 86. 1999
Evaluation of chest computed tomography in the staging of patients with potentially resectable liver metastases from colorectal carcinoma.. 86. 1999
The cytology of extraskeletal Ewing sarcoma.. 87. 1999
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.. 85. 1999
B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology.. 85. 1999
Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma.. 85. 1999
Malignant fibrous histiocytoma of the extremity.. 85. 1999
Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma.. 85. 1999
Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy.. 85. 1999
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.. 85. 1999
Childhood melanoma survival.. 85. 1999
Genetic changes in the spectrum of neuroendocrine lung tumors.. 85. 1999
Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma.. 85. 1999
Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.. 85. 1999
Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.. 83. 1998
Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group.. 83. 1998
Malignant vascular tumors in young patients.. 83. 1998
Skeletal and extraskeletal myxoid chondrosarcoma: a comparative clinicopathologic, ultrastructural, and molecular study.. 83. 1998
Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.. 83. 1998
The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States.. 83. 1998
A Phase II clinical trial of idarubicin administered to children with relapsed brain tumors.. 83. 1998
A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain.. 83. 1998
Gallbladder carcinoma discovered during laparoscopic cholecystectomy: aggressive reresection is beneficial.. 83. 1998
Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma.. 83. 1998
Survival of premenopausal women with breast carcinoma: effects of menstrual timing of surgery.. 83. 1998
Pathologic femoral fracture after periosteal excision and radiation for the treatment of soft tissue sarcoma.. 82. 1998
Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: a clinicopathologic study of 25 patients and 26 tumors.. 82. 1998
The number of positive margins influences the outcome of women treated with breast preservation for early stage breast carcinoma.. 82. 1998
Preoperative galactography increases the diagnostic yield of major duct excision for nipple discharge.. 82. 1998
Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study.. 82. 1998
The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant.. 82. 1998
A comparison of screening mammography results from programs for women of different socioeconomic status.. 82. 1998
Prognostic factors for patients with sarcomas of the pelvic bones.. 82. 1998
Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity.. 82. 1998
Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.. 82. 1998
The role of surgery in the treatment of clinically isolated adrenal metastasis.. 82. 1998
Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery.. 82. 1998
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding.. 80. 1997
Single chain antigen binding protein (sFv CC49): first human studies in colorectal carcinoma metastatic to liver.. 80. 1997
Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia.. 80. 1997
9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.. 80. 1997
Results of hospital cancer registry surveys by the American College of Surgeons: outcomes of prostate cancer treatment by radical prostatectomy.. 80. 1997
Surgical treatment of 70 patients with brain metastases from breast carcinoma.. 80. 1997
Chest wall rhabdomyosarcoma.. 80. 1997
Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors.. 80. 1997
Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells.. 80. 1997
Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma.. 80. 1997
The conservative management of Paget's disease of the breast with radiotherapy.. 80. 1997
The role of dietary factors in the intestinal and diffuse histologic subtypes of gastric adenocarcinoma: a case-control study in the U.S.. 80. 1997
Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors.. 80. 1997
Kaposi's sarcoma-associated herpesvirus sequences in benign lymphoid proliferations not associated with human immunodeficiency virus.. 80. 1997
Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma/primitive neuroectodermal tumors: a comparison of hyperfractionated versus conventional radiotherapy.. 80. 1997
Psychologic aspects of cancer genetic testing: a research update for clinicians.. 80. 1997
The American Society of Clinical Oncology position on genetic testing: implications for health care providers: workshop no. 4.. 80. 1997
Influence of nativity on cancer mortality among black New Yorkers.. 80. 1997
Fine-needle aspiration biopsy in the diagnosis and management of bone lesions: a study of 450 cases.. 81. 1997
Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study Group.. 79. 1997
Solitary fibrous tumor. A cytologic-histologic study with clinical, radiologic, and immunohistochemical correlations.. 81. 1997
All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group.. 79. 1997
Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis.. 79. 1997
p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate.. 79. 1997
Patterns of mammographically detected calcifications after breast-conserving therapy associated with tumor recurrence.. 79. 1997
Cutaneous melanoma in patients with sarcoma.. 79. 1997
Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome.. 79. 1997
Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma.. 79. 1997
Small cell neuroendocrine carcinoma of the urinary bladder. A clinicopathologic study with emphasis on cytologic features.. 79. 1997
A national survey of attitudes regarding participation in prostate carcinoma testing.. 78. 1996
A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.. 78. 1996
Acute complications of central line placement in profoundly thrombocytopenic cancer patients.. 78. 1996
Clinical presentations and RET protooncogene mutations in seven multiple endocrine neoplasia type 2 kindreds.. 78. 1996
Graft-versus-host disease. Possible higher risk for African American patients.. 78. 1996
The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society.. 78. 1996
Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index.. 78. 1996
Transitions in the care of adolescent and young adult survivors of childhood cancer.. 78. 1996
Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response.. 78. 1996
Current prognostic factors and their relevance to staging.. 78. 1996
Treatment of femoral Ewing's sarcoma.. 78. 1996
United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females.. 77. 1996
Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.. 77. 1996
Post-irradiation malignant mesothelioma.. 77. 1996
The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis.. 77. 1996
Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome.. 77. 1996
Second malignant neoplasms in long-term survivors of childhood rhabdomyosarcoma.. 76. 1995
Surgery with adjuvant irradiation in patients with pathologic stage C adenocarcinoma of the prostate.. 76. 1995
The National Cancer Data Base report on pancreatic cancer.. 76. 1995
The impact of mammography in 1096 consecutive patients with breast cancer, 1979-1993: equal value for patients younger and older than age 50 years.. 76. 1995
High grade soft tissue sarcoma of the flexor fossae. Size rather than compartmental status determine prognosis.. 76. 1995
p53 protein accumulation in tumors of the ampulla of Vater.. 76. 1995
Characteristics of follicular tumors and nonneoplastic thyroid lesions in children and adolescents exposed to radiation as a result of the Chernobyl disaster.. 76. 1995
Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin.. 76. 1995
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.. 76. 1995
all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial.. 76. 1995
Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel.. 76. 1995
A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma.. 75. 1995
A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.. 75. 1995
A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer.. 75. 1995
Assessment of response to therapy of primary breast cancer by mammography and physical examination.. 75. 1995
Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis.. 75. 1995
Inadequate adherence to radiotherapy in Latina immigrants with carcinoma of the cervix. Potential impact on disease free survival.. 75. 1995
Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.. 75. 1995
A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer.. 75. 1995
Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.. 75. 1995
Prevalence and predictors of continued tobacco use after treatment of patients with head and neck cancer.. 75. 1995
The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate.. 75. 1995
Lung cancer.. 75. 1995
Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer.. 75. 1995
Dysplastic nevi as a melanoma risk factor in patients with familial melanoma.. 74. 1994
Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse.. 74. 1994
A phase I trial of intrahepatic verapamil and doxorubicin. Regional therapy to overcome multidrug resistance.. 74. 1994
A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer.. 74. 1994
In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer.. 74. 1994
Conservative surgery for giant cell tumors of the sacrum. The role of cryosurgery as a supplement to curettage and partial excision.. 74. 1994
Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.. 74. 1994
The management of high grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem.. 74. 1994
A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors.. 74. 1994
Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas.. 74. 1994
Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas.. 74. 1994
The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations.. 74. 1994
Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas.. 73. 1994
Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases.. 73. 1994
The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. The Memorial Sloan-Kettering Cancer Center experience.. 73. 1994
Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.. 73. 1994
Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care.. 73. 1994
Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.. 73. 1994
Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale.. 73. 1994
Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma.. 73. 1994
Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update.. 73. 1994
Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia.. 73. 1994
Radiobiologic studies of low-dose-rate 90Y-lymphoma therapy.. 73. 1994
The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin.. 73. 1994
Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer.. 73. 1994
Therapy of venous thromboembolism in patients with brain metastases.. 73. 1994
Defining the invasive phenotype of proximal gastric cancer cells.. 73. 1994
Expression of bone morphogenetic proteins in human osteosarcoma. Immunohistochemical detection with monoclonal antibody.. 73. 1994
Partial nephrectomy for renal cell carcinoma with a normal opposite kidney.. 73. 1994
Phase II trial of gemcitabine in patients with advanced gastric cancer.. 73. 1994
The effect of age at diagnosis on outcome in rhabdomyosarcoma.. 73. 1994
Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial.. 72. 1993
CD30 (Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus.. 72. 1993
Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol.. 72. 1993
Expression and modulation of class I and class II histocompatibility leukocyte antigens on human soft tissue sarcomas.. 72. 1993
Liposarcoma in patients younger than or equal to 22 years of age.. 72. 1993
Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis.. 72. 1993
Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy.. 72. 1993
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder.. 72. 1993
Characterization of cell lines established from human gastric-esophageal adenocarcinomas. Biologic phenotype and invasion potential.. 72. 1993
Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma.. 72. 1993
The clinical spectrum of ocular lymphoma.. 72. 1993
A phase II trial of carboplatin in patients with advanced APUD tumors.. 72. 1993
Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors.. 72. 1993
Prognosis of operable squamous cell carcinoma of the esophagus. Relationship with clinicopathologic features and DNA ploidy.. 72. 1993
Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.. 71. 1993
The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer.. 71. 1993
Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment.. 71. 1993
Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.. 71. 1993
Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment.. 71. 1993
Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.. 71. 1993
A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases.. 71. 1993
Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma.. 71. 1993
Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.. 71. 1993
Phase II trial of carboplatin and etoposide in metastatic breast cancer.. 71. 1993
A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy.. 71. 1993
The role of neoadjuvant hormonal manipulation in localized prostatic cancer.. 71. 1993
Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience.. 71. 1993
Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy.. 71. 1993
Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy.. 70. 1992
Long-term treatment results of postoperative radiation therapy for advanced stage oropharyngeal carcinoma.. 70. 1992
Spinal epidural tumor in patients with prostate cancer. Clinical and radiographic predictors of response to radiation therapy.. 70. 1992
Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers.. 70. 1992
Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. The Cancer and Leukemia Group B.. 70. 1992
A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.. 70. 1992
Epstein-Barr virus in acquired immune deficiency syndrome (AIDS) and non-AIDS primary central nervous system lymphoma.. 70. 1992
Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect.. 70. 1992
Prognostic significance of DNA quantitation in stage D1 prostate carcinoma with the use of image analysis.. 70. 1992
The National Polyp Study. Design, methods, and characteristics of patients with newly diagnosed polyps. The National Polyp Study Workgroup.. 70. 1992
Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas.. 70. 1992
Detection of local recurrence after conservative therapy for breast carcinoma.. 70. 1992
Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience.. 70. 1992
Tendosynovial sarcoma. Clinicopathologic features, treatment, and prognosis.. 70. 1992
Surgical treatment for benign prostatic hyperplasia.. 70. 1992
Is screening for breast cancer cost-effective?. 69. 1992
Legal aspects, legislative effect, cost effectiveness, and barriers to breast cancer screening.. 69. 1992
Four cycles of chemotherapy and regional radiation therapy for clinical early-stage and intermediate-stage Hodgkin's disease.. 69. 1992
Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump.. 69. 1992
Correlation between side of palpable tumor and side of pelvic lymph node metastasis in clinically localized prostate cancer.. 69. 1992
Preoperative imaging of colorectal cancers. Targeting the epithelial membrane antigen with a radiation-labeled monoclonal antibody.. 69. 1992
Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience.. 69. 1992
The indications for elective treatment of the neck in cancer of the major salivary glands.. 69. 1992
A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer.. 69. 1992
High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated.. 69. 1992
A flow cytometric study of non-small cell lung cancer classified as T1N0.. 69. 1992
Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors.. 68. 1991
Ten-year results of breast-conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma in situ) of the breast.. 68. 1991
An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2.. 68. 1991
Transurethral resection of the prostate and metastatic prostate cancer.. 68. 1991
Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B.. 68. 1991
Localization of endocrine tumors of the pancreas with endoscopic ultrasonography.. 68. 1991
A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.. 68. 1991
A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors.. 68. 1991
Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia.. 68. 1991
A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.. 68. 1991
Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens.. 68. 1991
Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure.. 68. 1991
High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma.. 68. 1991
Preoperative high-dose leucovorin/5-fluorouracil and radiation therapy for unresectable rectal cancer.. 67. 1991
Retinoblastoma. The long-term appearance of radiated intraocular tumors.. 67. 1991
Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma.. 67. 1991
Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features.. 67. 1991
Extracranial primitive neuroectodermal tumors. The Memorial Sloan-Kettering Cancer Center experience.. 67. 1991
Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy.. 67. 1991
Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989).. 67. 1991
Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors.. 67. 1991
A phase II trial of carboplatin and vinblastine in the treatment of advanced squamous cell carcinoma of the esophagus.. 67. 1991
Combined surgical resection and iridium 192 implantation for locally advanced and recurrent desmoid tumors.. 67. 1991
Insulin secretion and action in patients with pancreatic cancer.. 67. 1991
Two-drug therapy in patients with metastatic germ cell tumors.. 67. 1991
Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity.. 66. 1990
The role of autologous tumor cells in preventing lymphokine-activated killer cell induction in vitro.. 66. 1990
The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors.. 66. 1990
A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.. 66. 1990
A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies.. 66. 1990
Comparison of the conventional method of lymph node staging with a comprehensive fat-clearing method for gastric adenocarcinoma.. 66. 1990
Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer.. 66. 1990
Cellular schwannoma. A clinicopathologic study of 57 patients and 58 tumors.. 66. 1990
Dose-intensive use of cyclophosphamide in ablation of neuroblastoma.. 66. 1990
Radiation therapy after breast augmentation or reconstruction in early or recurrent breast cancer.. 66. 1990
The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patients.. 66. 1990
A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma.. 66. 1990
Delayed central nervous system (CNS) radiation in childhood CNS acute lymphoblastic leukemia. Results of a pilot trial.. 66. 1990
Targeted cytogenetic analysis of gastric tumors by in situ hybridization with a set of chromosome-specific DNA probes.. 66. 1990
The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity.. 66. 1990
Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors.. 65. 1990
Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma.. 65. 1990
DNA content of rectal scrapings from individuals at low and high risk for the development of colorectal cancer. A feasibility study.. 64. 1989
Diaziquone and 2,2'-anhydro-arabinosyl-5-fluorocytosine for the treatment of children with relapsed or refractory acute nonlymphoblastic leukemia.. 64. 1989
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.. 64. 1989
Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma.. 64. 1989
Small cell carcinoma of the esophagus. The Memorial Hospital experience 1970 to 1987.. 64. 1989
The prognostic value of histologic subtypes in primary extremity liposarcoma.. 64. 1989
Individual risk of abdominal disease in patients with stages I and II supradiaphragmatic Hodgkin's disease. A rule index based on 341 laparotomized patients.. 63. 1989
Reinduction therapy for advanced or refractory acute lymphoblastic leukemia of childhood.. 63. 1989
Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates.. 63. 1989
Primary central nervous system lymphoma in AIDS. Results of radiation therapy.. 63. 1989
Interstitial brachytherapy for metastatic brain tumors.. 63. 1989
Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement.. 63. 1989
Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors.. 63. 1989
The problem of neck relapse in early stage supraglottic larynx cancer.. 63. 1989
Alveolar soft-part sarcoma. A clinico-pathologic study of half a century.. 63. 1989
Peripheral T-cell lymphoma.. 63. 1989
Flow cytometric analysis of pituitary tumors. Correlation of nuclear antigen p105 and DNA content with clinical behavior.. 62. 1988
Significance of systemic mast cell disease with associated hematologic disorders.. 62. 1988
Low-grade soft tissue sarcomas of the extremities. Analysis of risk factors for metastasis.. 62. 1988
AIDS-related lymphoid neoplasia. The Memorial Hospital experience.. 61. 1988
Long-term survival after resection of ampullary carcinoma is associated independently with tumor grade and a new staging classification that assesses local invasiveness.. 61. 1988
Patient compliance with aggressive multimodal therapy in locally advanced breast cancer.. 61. 1988
Cholecystectomy and adenomatous polyps of the colon in women.. 61. 1988
Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial.. 60. 1987
A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B.. 60. 1987
Distinguishing features of primary hyperparathyroidism in patients with breast cancer.. 60. 1987
The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma.. 60. 1987
Quality of life measurement in testicular cancer patients.. 60. 1987
The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain.. 60. 1987
The practical use of tumor marker determination in bladder washing specimens. Assessing the urothelium of patients with superficial bladder cancer.. 60. 1987
Malignant lymphomas in a population at risk for acquired immune deficiency syndrome.. 60. 1987
Abnormal colony formation and prostaglandin E responsiveness of myeloid progenitor cells in patients cured of germ cell neoplasms after combination chemotherapy.. 60. 1987
Monoclonal antibodies in urologic oncology.. 60. 1987
Strategies for the management of recurrent and advanced urologic cancers. Quality of life.. 60. 1987
Toxicity of intravesical BCG and its management in patients with superficial bladder tumors.. 60. 1987
Urologic cancer. Methods of early detection and future developments.. 60. 1987
Testicular failure in patients with extragonadal germ cell tumors.. 60. 1987
The sensitivity of flow cytometry compared with conventional cytology in the detection of superficial bladder carcinoma.. 59. 1987
Acute chest pain syndrome during bleomycin infusions.. 59. 1987
Smoking, body weight, and early-stage endometrial cancer.. 59. 1987
Lactase dehydrogenase as a tumor marker for recurrent disease in Ewing's sarcoma.. 59. 1987
Intermittent endocrine therapy for advanced prostate cancer.. 58. 1986
A pilot study of cisplatin-vinblastine as the initial treatment of advanced head and neck cancer.. 58. 1986
The treatment of single brain metastasis from non-oat cell lung carcinoma. Surgery and radiation versus radiation therapy alone.. 58. 1986
Thymomas. A review of 169 cases, with particular reference to results of surgical treatment.. 58. 1986
Clinical study of a new antimetastatic compound, Nafazatrom (Bay g 6575). Effects on platelet consumption and monocyte prostaglandin production in patients with advanced cancer.. 57. 1986
Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors.. 57. 1986
Limb preservation and tumor control in the treatment of popliteal and antecubital soft tissue sarcomas.. 57. 1986
Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors.. 57. 1986
Transrectal ultrasonography for prostatic cancer. II. The response of the prostate to definitive radiotherapy.. 57. 1986
Small cell carcinoma cell lines contain opioid peptides and receptors.. 57. 1986
Intraluminal radiation therapy in the management of malignant biliary obstruction.. 57. 1986
Increased survival with high-dose multifield radiotherapy and intensive chemotherapy in limited small cell carcinoma of the lung.. 56. 1985
Hairy cell leukemia. Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients.. 56. 1985
Adenocarcinoma of the esophagus and gastroesophageal junction. Prognostic factors and results of therapy.. 56. 1985
The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines.. 56. 1985
Metastatic neuroblastoma and testicular involvement.. 56. 1985
Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial.. 56. 1985
Fasting plasma amino acid levels in cancer patients.. 56. 1985
Preoperative intra-arterial infusion chemotherapy for advanced squamous cell carcinoma of the mouth and oropharynx.. 56. 1985
Retroperitoneal germ cell tumors in childhood. A clinical and pathologic study of 11 cases.. 56. 1985
HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification.. 55. 1985
Terminal deoxynucleotidyl transferase activity in childhood leukemia.. 55. 1985
A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk.. 55. 1985
Correlation of erythrocyte and plasma levels of zinc, copper, and iron with evidence of metastatic spread in cancer patients.. 55. 1985
Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells.. 55. 1985
Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.. 55. 1985
Glucose intolerance in sarcoma patients.. 54. 1984
Cisplatin and bleomycin in the treatment of esophageal carcinoma. A final report.. 54. 1984
Metabolic consequences of nutritional support of the cancer patient.. 54. 1984
Monoclonal antibodies to breast cancer-associated antigens as potential reagents in the management of breast cancer.. 54. 1984
New therapeutic approaches for brain tumors.. 54. 1984
The efficacy of routine whole lung tomography in germ cell tumors.. 54. 1984
Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy.. 54. 1984
T-lymphocyte subpopulations in B-cell-derived non-Hodgkin's lymphomas and Hodgkin's disease.. 54. 1984
Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in Phase II trial of flutamide.. 54. 1984
Intracranial metastases in prostate cancer.. 53. 1984
NHL-3 protocol. Six-drug combination chemotherapy for non-Hodgkin's lymphoma.. 53. 1984
Treatment of diffuse poorly differentiated lymphocytic lymphoma. An analysis of prognostic variables.. 53. 1984
Testicular function following bone marrow transplantation performed during or after puberty.. 53. 1984
Comparison of antigen expression of human renal cancers in vivo and in vitro.. 53. 1984
Does clearing of axillary lymph nodes contribute to accurate staging of breast carcinoma?. 53. 1984
Intraarterial versus intravenous adriamycin in the rabbit Vx-2 tumor system.. 53. 1984
Potentiation of methylglyoxal-bis-guanylhydrazone by alpha-difluoromethylornithine in rat prostate cancer.. 53. 1984
Vertebral body resection in the treatment of cancer involving the spine.. 53. 1984
Whole-body protein metabolism in cancer-bearing patients. Effect of total parenteral nutrition and associated serum insulin response.. 53. 1984
Adult non-Hodgkin's lymphoma. Correlation of cell surface marker phenotype with prognosis, the new working formulation, and the Rappaport and Lukes-Collins histomorphologic schemes.. 52. 1983
Planned preoperative cisplatin and radiation therapy for locally advanced bladder cancer.. 52. 1983
Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group.. 52. 1983
Cooperative groups and community hospitals. Measurement of impact in the community hospitals.. 52. 1983
Reactivity of monoclonal antibodies Leu 1 and OKT1 with malignant human lymphoid cells. Correlation with conventional cell markers.. 52. 1983
Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities.. 52. 1983
Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testis.. 51. 1983
Severe pneumococcal infection in patients with neoplastic disease.. 51. 1983
Effect of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder.. 51. 1983
Inferior pubic rami resection with en bloc radical excision for invasive proximal urethral carcinoma.. 51. 1983
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone.. 51. 1983
Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer.. 51. 1983
Association of depressed mixed lymphocyte reactivity with the development of bladder carcinoma in patients with papillomas.. 51. 1983
Metastatic colorectal carcinoma. A prospective randomized trial of Methyl-CCNU, 5-Fluorouracil (5-FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF-Strep).. 51. 1983
The non-Hodgkin's lymphomas. I. A retrospective clinical and pathologic analysis of 499 cases diagnosed between 1958 and 1969.. 51. 1983
VAB-6 combination chemotherapy in resected stage II-B testis cancer.. 51. 1983
Cytogenetic findings in the dysmyelopoietic syndrome.. 50. 1982
Treatment of advanced esophageal cancer.. 50. 1982
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.. 50. 1982
Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma.. 50. 1982
Intravenous cisplatin for superficial bladder tumors.. 50. 1982
Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up.. 50. 1982
Characterization of two newly established human cell lines from patients with large-cell anaplastic lung carcinoma.. 50. 1982
Tumor classification and size in germ-cell testicular cancer: influence on the occurrence of metastases.. 50. 1982
Role of chemotherapy and surgery in the treatment of thoracic metastases from nonseminomatous germ cell testis tumor.. 50. 1982
Soft tissue sarcomas of the extremities: survival and patterns of failure with conservative surgery and postoperative irradiation compared to surgery alone.. 50. 1982
An evaluation of automated flow cytometry (FCM) in detection of carcinoma in situ of the urinary bladder.. 50. 1982
Intravesical cisplatin for superficial bladder tumors.. 50. 1982
Detection and follow-up of carcinoma of the urinary bladder by flow cytometry.. 50. 1982
Cell kinetics in acute leukemia: a critical reevaluation based on new data.. 50. 1982
The immunologic characterization of 40 extranodal lymphoid infiltrates: usefulness in distinguishing between benign pseudolymphoma and malignant lymphoma.. 49. 1982
Treatment of advanced diffuse histiocytic lymphoma: an analysis of prognostic variables.. 49. 1982
A controlled, prospective, randomized trial evaluating the metabolic effects of enteral and parenteral nutrition in the cancer patient.. 49. 1982
Combination chemotherapy of esophageal carcinoma using cisplatin, vindesine, and bleomycin.. 49. 1982
Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.. 49. 1982
Resting and activity energy expenditure during total parenteral nutrition in rats with methylcholanthrene-induced sarcoma.. 49. 1982
The impact of total parenteral nutrition on liver function tests in patients with cancer.. 49. 1982
Correlation of histochemical and biochemical analyses of androgen binding in prostatic cancer: relation to therapeutic response.. 49. 1982
Preoperative irradiation and cystectomy for bladder cancer.. 49. 1982
Immunoregulation by blasts from null cell and T-cell leukemias: help and suppression of T-cell proliferative responses to mitogens.. 49. 1982
Comparison of the response to PHA and suppressor macrophage function in different age groups of cancer patients and healthy controls.. 48. 1981
Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer.. 48. 1981
Treatment of acute nonlymphocytic leukemia in adults: response to 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine and thioguanine on the L-12 protocol.. 48. 1981
Small cell lung cancer: analysis of treatment factors contributing to prolonged survival.. 48. 1981
Osteonecrosis in patients with malignant lymphoma: a review of twenty-five cases.. 48. 1981
Multivariate analysis of T-cell functional defects and circulating serum factors in Hodgkin's disease.. 48. 1981
Adjuvant chemotherapy with VAB-3 of stage II-B testicular cancer.. 48. 1981
Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum.. 48. 1981
Combined modality therapy of esophageal carcinoma.. 48. 1981
DNCB reactivity and prognosis in 419 patients with malignant melanoma.. 47. 1981
Combined chemotherapy and surgery in treatment of advanced germ-cell tumors.. 47. 1981
Ewing's sarcoma: ten-year experience with adjuvant chemotherapy.. 47. 1981
Metabolic alterations in a noncachectic animal tumor system.. 47. 1981
The continuing challenge of retroperitoneal sarcomas.. 47. 1981
Adjuvant chemotherapy combination of vinblastine, actinomycin D, Bleomycin, and Chlorambucil following retroperitoneal lymph node dissection for stage II testis tumor.. 47. 1981
Tumor markers in advanced nonseminomatous testicular cancer.. 47. 1981
Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer.. 47. 1981
Immunotherapy with oral BCG and serial immune evaluation in childhood lymphoblastic leukemia following three years of chemotherapy.. 46. 1980
Serum zinc, copper, and the Cu/Zn ratio in patients with benign and malignant breast lesions.. 46. 1980
Pharmacokinetics of gallium nitrate in man.. 46. 1980
Immunologic reactivity and prognosis in breast cancer.. 46. 1980
A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease.. 46. 1980
Analysis of multiple cell markers in acute leukemia complicating Hodgkin's disease.. 46. 1980
Extracardiac rhabdomyoma: a clinicopathologic study and review of the literature.. 46. 1980
Intensive five-drug combination chemotherapy for adult acute non-lymphocytic leukemia.. 46. 1980
Orbital lymphoid neoplasms: a clinicopathologic study of 60 patients.. 46. 1980
A long-term clinical follow-up of children with acute lymphoblastic leukemia treated with intensive chemotherapy regimens.. 46. 1980
The eight-drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease: a follow-up report.. 46. 1980
Prognostic significance of serum lactate dehydrogenase in malignant lymphoma.. 46. 1980
Subpopulations of human T lymphocytes. VI. Analysis of cell markers in acute lymphoblastic leukemia with special reference to Fc receptor expression on E-rosette-forming blasts.. 46. 1980
In vivo utilization of substrate by human sarcoma-bearing limbs.. 45. 1980
A study of adriamycin-reduced wound breaking strenght in rats. An evaluation by light and electron microscopy, induction of collagen maturation, and hydroxyproline content.. 45. 1980
Time dependent effects of adriamycin and x-ray therapy on wound healing in the rat.. 45. 1980
Association of Kaposi's sarcoma with second primary malignancies: possible etiopathogenic implications.. 45. 1980
Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.. 45. 1980
Immunotherapy of colon cancer: prospects for developing immunogenic vaccines based on autologous serological typing.. 45. 1980
Influenza immunization of children with neoplastic diseases.. 45. 1980
Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: a comparative study to surgical resection.. 45. 1980
Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B.. 45. 1980
Effect of short-term levamisole therapy on delayed hypersensitivity.. 45. 1980
Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatment.. 44. 1979
A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II.. 44. 1979
Acute non-lymphocytic leukemia and acute myeloproliferative syndrome following radiation therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia: cytogenetic studies.. 44. 1979
Acute nonlymphocytic leukemia and acute myeloproliferative syndrome following radiation therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia: clinical studies.. 44. 1979
A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non-Hodgkin's lymphoma.. 43. 1979
The quantitative and qualitative impairment of wound healing by adriamycin.. 43. 1979
A randomized study of two different schedules of methyl CCNU, 5-FU and vincristine for metastatic colorectal carcinoma.. 43. 1979
Anticoagulation and high dose liver radiation: a preliminary report.. 43. 1979
The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine.. 43. 1979
Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.. 42. 1978
Cardiac candidiasis in cancer patients.. 41. 1978
Diamminedichloride platinum II and cyclophosphamide in the treatment of advanced urothelial cancer.. 41. 1978
Prophylactic heparin therapy in acute promyelocytic leukemia.. 41. 1978
Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma.. 41. 1978
Results of combined chemo-surgical therapy for pulmonary metastases from testicular carcinoma.. 41. 1978
Immunologic reactivity in patients with primary operable breast cancer.. 41. 1978
NMR in cancer. X. A malignancy index to discriminate normal and cancerous tissue.. 41. 1978
NMR in cancer. XI. Application of the NMR malignancy index to human gastro-intestinal tumors.. 41. 1978
High dose methotrexate with citrovorum factor in adult resistant lymphoma.. 40. 1977
The treatment of mycosis fungoides: adjuvant topical mechlorethamine after electron beam therapy.. 40. 1977
Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using and indirect immunoperoxidase technique.. 40. 1977
The long term effects of radiation of T and B lymphocytes in the peripheral blood after regional irradiation.. 40. 1977
Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up.. 40. 1977
Patterns of second malignant neoplasms in children.. 40. 1977
The coexistence of nodular and diffuse patterns in nodular non-Hodgkin's lymphomas: significance and clinicopathologic correlation.. 40. 1977
Radiotherapy results for nodular sclerosing Hodgkin's disease after clinical staging.. 39. 1977
A comparative study of some pathologic features of mammary carcinoma in Tokyo, Japan and New York, USA.. 39. 1977
Intravenous Corynebacterium parvum: an adjunct to chemotherapy for resistant advanced ovarian cancer.. 39. 1977
The role of bone marrow aspiration and biopsy in detecting marrow involvement by nonhematologic malignancies.. 38. 1976
Intrathecal N, N', N"-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: phase I-II study.. 38. 1976
Proximal tubular adenomas of kidney with so-called oncocytic features. A clinicopathologic study of 13 cases of a rarely reported neoplasm.. 38. 1976
Abdominal irradiation in non-Hodgkin's lymphomas.. 37. 1976
Non-Hodgkin's lymphomas of stage III extent. Is total lymphoid irradiation appropriate treatment?. 37. 1976
Acute lymphoblastic leukemia in adults and children. Differences in response with similar therapeutic regimens.. 37. 1976
Decreased risk of radiation-associated second malignant neoplasms in actinomycin-D-treated patients.. 37. 1976
Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia.. 36. 1975
Treatment of acute leukemia in adults.. 36. 1975
Quantitation of T and B lymphocytes and cellular immune function in Hodgkin's disease.. 36. 1975
Studies of cellular proliferation in human leukemia. VIII. The generation time and growth fraction in lymphosarcoma in a leukemic phase during advanced and early relapsing disease.. 36. 1975
Explorotory study of proton radiation therapy using large field techniques and fractionated dose schedules.. 35. 1975
Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors.. 35. 1975
Full thickness chest wall resection for recurrent breast carcinoma involving the bony chest wall.. 35. 1975
Indications for pleurectomy in malignant effusion.. 35. 1975
Multidisciplinary treatment of embryonal rhabdomyosarcoma in children.. 35. 1975
Of birds and mice and men: comments on the use of animal models and molecular hybridization in the search for human tumor viruses.. 34. 1974
Lymphography in mycosis fungoides.. 34. 1974
The role of lymphography in patients with ovarian cancer.. 34. 1974
Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol).. 33. 1974
Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.. 33. 1974
Prognostic signs and the management of the mycosis fungoides.. 32. 1973
Proceedings: Combination therapy of urogenital embryonal rhabdomyosarcoma in children.. 32. 1973
Non-Hodgkin's lymphomas. V. Results of radiotherapy.. 32. 1973
Staging laparotomies in unselected previously untreated patients with non-Hodgkin's lymphomas.. 32. 1973
Liver-spleen scan in Hodgkin's disease.. 31. 1973
Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases.. 31. 1973
Survival in chronic myelogenous leukemia: influence of treatment and extent of disease at diagnosis.. 31. 1973
Reappraisal of surgical management of sarcoma of the buttock.. 31. 1973
Acute myelocytic leukemia in adults.. 30. 1972
Chondroblastoma of bone. A clinicopathologic and electron microscopic study.. 29. 1972
Cyclic chemotherapy in lymphoma.. 28. 1971
Studies on cellular proliferation in human leukemia. VII. Cytokinetic behavior of neoplastic cells in a patient with reticulum cell sarcoma in a leukemic phase.. 28. 1971
Aneurysmal bone cysts. A clinicopathologic study of 66 cases.. 26. 1970
Incontinuity versus discontinuous lymph node dissection for malignant melanoma.. 26. 1970
Prognostic significance of lymph node dissection in the treatment of malignant melanoma.. 26. 1970
Importance of bone marrow biopsy in the clinical staging of Hodgkin's disease.. 26. 1970
Studies of cellular proliferation in human leukemia. IV. Behavior of normal hemotopoietic cells in 3 adults with acute leukemia given continuous infusions of 3H-thymidine for 8 or 10 days.. 26. 1970
Studies of cellular proliferation in human leukemia. 3. Behavior of leukemic cells in three adults with acute leukemia given continuous infusions of 3H-thymidine for 8 or 10 days.. 25. 1970
Studies of cellular proliferation in human leukemia. VI. The proliferative activity, generation time, and emergence time of neutrophilic granulocytes in chronic granulocytic leukemia.. 25. 1970
Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors.. 25. 1970
E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children.. 25. 1970
L-asparaginase activity in plasma and other biological fluids.. 25. 1970
Toxicity of E. coli L-asparaginase in man.. 25. 1970
Heterotransplantability of human cell lines derived from leukemia and lymphomas into immunologically tolerant rats.. 24. 1969
Treatment of adult acute leukemia with arabinosylcytosine and thioguanine.. 23. 1969
Hetero- transplantation of human cell lines from Burkitt's tumors and acute leukemia into newborn rats.. 23. 1969
Extraskeletal spread in multiple plasma cell myeloma. A review of 57 autopsied cases.. 23. 1969
Two histologically different primary carcinomas of the lung. A review of the literature and presentation of a case.. 22. 1968
Continuous culture of seven new cell lines (SK-L1 to 7) from patients with acute leukemia.. 20. 1967
Electron microscopic study of human leukemic cells in tissue culture.. 20. 1967
Kinetics of proliferation of cancer cells in neoplastic effusions in man.. 18. 1965
CYTOPATHOLOGICAL CORRELATIONS IN TUMORS OF THE URINARY BLADDER.. 17. 1964
RELATIONSHIP BETWEEN CELL TYPE, GLUCOSE CONCENTRATION, AND RESPONSE TO TREATMENT IN NEOPLASTIC EFFUSIONS.. 17. 1964
Malignant lymphoma involving the jaw in African children: treatment with Methotrexate.. 16. 1963
Effects of continuous hepatic artery infusion of antimetabolites on primary and metastatic cancer of the liver.. 15. 1962
Antimetabolite-metabolite cancer chemotherapy using continuous intra-arterial methotrexate with intermittent intramuscular citrovorum factor. Method of therapy.. 14. 1961
The 2008 European School of Oncology inside track conference, "predictive modeling in prostate cancer".. 115. 2009
Reply to Urinary toxicity after stereotactic body radiotherapy: The boy who cried wolf? 2016
Reply to The risk factors of upgrading in prostate cancer. 2020
Reply to Hope, optimism, and the importance of caregivers in end-of-life care. 2019
Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today? 2019
Reply to Distinguishing between CISNET model results versus CISNET models. 2017
Reply to Opportunity cost of annual screening mammography. 2017
Reply to "Twistin' the night away": Fertility preservation in young adult female cancer survivors. 2016
Reply to breast cancer risk by the extent and type of atypical hyperplasia. 2016
BRCA2-associated pancreatic cancer and current screening guidelines. 2015
Reply to discrepant results for smoking and cessation among electronic cigarette users. 2015
Reply to US lung cancer trends by histologic type. 2014
Reply to Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients. 2013
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. 2011
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. 2010
Increasing the pool of academically oriented African-American medical and surgical oncologists. 2003
Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. 2003
Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma. 2003
Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease. 1998
Autologous bone marrow transplantation in children with advanced neuroblastoma. 1995
Comparative study of infectious complications of different types of chronic central venous access devices. 1995
Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. 2010
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. 2008
Proceedings of the Consensus Conference on Breast Conservation, April 28 to May 1, 2005, Milan, Italy. 2006
Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. 2004
Overview of the summit meeting evaluating research in African-American women. 2003
Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. 2002
Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22-25, 1999. 2000
Nasopharynx cancer: Induction or adjuvant? That is the question.. 126. 2020
Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.. 124. 2018
Running the marathon of chronic myeloid leukemia with no shoes (or without the right shoes)!. 123. 2017
Missing the mark in FGFR1-amplified squamous cell cancer of the lung.. 122. 2016
Specialty care for adult survivors of childhood cancer.. 121. 2015
Notch inhibition in desmoids: "Sure it works in practice, but does it work in theory?".. 121. 2015
The time is now: assessing and addressing the needs of cancer caregivers.. 121. 2015
Inherited predisposition to endometrial cancer: moving beyond Lynch syndrome.. 121. 2014
Quality lung cancer screening protects quality of life: no harm, no foul.. 120. 2014
Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma.. 120. 2014
Is pediatric melanoma always malignant?. 119. 2013
Preoperative chemotherapy for bladder cancer: a standard waits to be optimally deployed.. 118. 2011
Technology impacting on biology: spine radiosurgery.. 117. 2011
Proceedings of the First International Inflammatory Breast Cancer Conference.. 116. 2010
Radiation versus resection for Merkel cell carcinoma.. 116. 2010
High-risk, high-grade (T1G3) bladder cancer: models versus reality.. 115. 2009
"Limited" prostate cancer on biopsy: a note of caution.. 112. 2008
The "microscopic" revolution in breast carcinoma.. 103. 2005
Breast carcinoma in African-American and White women: application of molecular biology to understand outcome disparities.. 101. 2004
Seeking the solution to the problem of metastatic renal carcinoma.. 97. 2003
Pathologic analysis of sentinel lymph nodes in breast carcinoma.. 88. 2000
Agonizing over AGUS.. 87. 1999
Progression of T1 bladder tumors: better staging or better biology?. 86. 1999
Hepatocellular carcinoma and coinfection with hepatitis B and C. Making a difficult situation worse.. 86. 1999
Parathyroid carcinoma: a diagnostic and therapeutic challenge.. 86. 1999
Understanding ductal carcinoma in situ: a step in the right direction.. 86. 1999
Economic analysis of expensive technologies: the case of erythropoietin.. 83. 1998
The National Cancer Data Base Report on thyroid carcinoma: reflections of practice patterns.. 83. 1998
Detectable tumor cells in the blood and bone marrow: smoke or fire?. 83. 1998
Thyroid carcinoma: implications of prognostic factors.. 83. 1998
The natural history of clinical prostate carcinoma.. 80. 1997
BRCA1. A new marker in the management of patients with breast cancer?. 77. 1996
The natural history of ductal carcinoma in situ. Implications for clinical decision making.. 76. 1995
Optimal treatment for advanced seminoma?. 72. 1993
Radical surgery for gastric cancer. A review of the Japanese experience.. 64. 1989
Defining disease modification in myelofibrosis in the era of targeted therapy. 2022
Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations. 2021
Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety. 2021
The METeoric rise of MET in lung cancer. 2020
The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. 2020
Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? 2019
Effects of psychosocial interventions on meaning and purpose in adults with cancer: A systematic review and meta-analysis. 2019
Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire? 2018
Risk-reducing salpingectomy: Let us be opportunistic. 2017
Current management and future directions in metastatic pancreatic adenocarcinoma. 2016
Irradiation and immunotherapy: From concept to the clinic. 2016
Social well-being among adolescents and young adults with cancer: A systematic review. 2016
New York Citywide Colon Cancer Control Coalition: A public health effort to increase colon cancer screening and address health disparities. 2015
Immunotherapy in hepatocellular carcinoma: Primed to make a difference? 2015
Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. 2015
Therapeutic targeting of tumor suppressor genes. 2014
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. 2014
Novel endoscopic diagnosis for bladder cancer. 2014
Treating advanced hepatocellular carcinoma: How to get out of first gear. 2014
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. 2012
Practical management of patients with chronic myeloid leukemia. 2011
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. 2010
Nomograms for staging, prognosis, and predicting treatment outcomes. 2009
The current state of brachytherapy nomograms for patients with clinically localized prostate cancer. 2009
Meta-analysis of sentinel lymph node positivity in thin melanoma ( 2009

Cancer screening and aging: research barriers and opportunities. 2008
An updated catalog of prostate cancer predictive tools. 2008
Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. 2008
Cognitive effects of hormone therapy in men with prostate cancer: a review. 2008
Systematic review of statistical methods used in molecular marker studies in cancer. 2008
Manipulating the chemokine-chemokine receptor network to treat cancer. 2007
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. 2005
Gemcitabine-related radiation recall preferentially involves internal tissue and organs. 2004
Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. 2003
Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. 2003
Overview of bladder cancer trials in the Cancer and Leukemia Group B. 2003
Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. 2003
RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. 2003
Breast cancer risk assessment models: applicability to African-American women. 2003
Treatment choices and response rates in African-American women with breast carcinoma. 2003
African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast. 2002
Ductal lavage and the clinical management of women at high risk for breast carcinoma: a commentary. 2002
Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. 2002
Rehabilitation for limb salvage patients: kinesiological parameters and psychological assessment. 2001
Rehabilitation of persons with central nervous system tumors. 2001
Strategies for managing cancer-related fatigue syndrome: a rehabilitation approach. 2001
Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center Experience and A Literature Review. 2001
Therapeutic choices in younger patients with chronic myelogenous leukemia. 2000
Novel strategies and therapeutics for the treatment of prostate carcinoma. 2000
Complications of bone metastases: surgical management. 2000
The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. 1999
Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience. 1998
Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. 1997
Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. 1996
Depression in patients with pancreatic carcinoma. Diagnostic and treatment issues. 1996
Selection criteria for breast conservation. The impact of young and old age and collagen vascular disease. 1994
Overview of clinical radioimmunodetection of human tumors. 1994
Mesenchymal chondrosarcoma of the orbit. Report of three new cases and review of the literature. 1994
Collision of transitional cell carcinoma and renal cell carcinoma. An immunohistochemical study and review of the literature. 1994
Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone. 1993
Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. 1993
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. 1993
Successful treatment of a desmoid tumor with doxorubicin. 1993
Imaging in gynecologic malignancies. 1993
Intraperitoneal chemotherapy in the management of ovarian cancer. 1993
Transgenic models for the study of prostate cancer. 1993
Recent advances in the treatment of advanced colorectal cancer. 1993
Leptomeningeal myelomatosis presenting with mental status changes and other neurologic findings. 1992
Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. 1992
The association of benign prostatic hyperplasia and cancer of the prostate. 1992
Type Ia glycogenosis associated with hepatocellular carcinoma. 1992
The malignant nature of papillary and cystic neoplasm of the pancreas. 1991
Carcinoma of the female reproductive organs. Value of cross-sectional imaging. 1991
Radioimmunology. Imaging and therapy. 1991
A meta-analysis of stages I and II Hodgkin's disease. 1990
Stereotaxic irradiation of brain tumors. 1990
Radical surgery for gastric cancer. A review of the Japanese experience. 1989
Management of cancer pain. Pharmacology and principles of management. 1989
Psychiatric management of cancer pain. 1989
Reduced incidence of the somnolence syndrome in leukemic children with steroid coverage during prophylactic cranial radiation therapy. Results of a pilot study. 1989
The association of progressive, atrophying, chronic, granulomatous dermohypodermitis with Hodgkin's disease. 1988
Advances in imaging. 1988
Second malignancies after childhood Hodgkin's disease. The Memorial Sloan-Kettering Cancer Center experience. 1988
State of the art in comparative cancer clinical trials. 1987
Radiation-induced angiosarcoma. 1987
Endodermal sinus tumor of the mediastinum. A report of seven cases and review of the literature. 1986
Harnessing T-lymphocytes for human cancer immunotherapy. 1985
Viruses, genes, and cancer. I. The discovery of cellular oncogenes and their role in neoplasia. 1985
Proliferative myositis of the masseter muscle. A case report and a review of the literature. 1983
Unusual presentation of bronchogenic carcinoma: case report and review of the literature. 1981
Metabolic response to surgery in the cancer patient: consequences of aggressive multimodality therapy. 1979
Carcinoma arising in a branchial cleft cyst. 1976
Long-term effects on external radiation on the pituitary and thyroid glands. 1976

VIVO Weill Cornell Medical College

Cancer Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)